Characterisation of anti-natalizumab antibodies in MS patients

This study from Sweden looked at the characterisation of anti-natalizumab antibodies in natalizumab-treated patients over a period of five years, as well as the persistence of the antibodies.

Standardised ELISA was carried out to detect anti-natalizumab antibodies in the cohort. The presence of anti-natalizumab antibodies is related to an increased risk of infusion-related adverse events, in addition to reduced clinical effect. Antibodies against natalizumab were detected in only 4.1% of the patients during treatment. The median treatment time was three months to the first positive sample, similar to previous studies. In the patients who tested positive, 35% reverted to negative and 33% remained persistently positive. They found that the titre level at three months can be predictive of which patients are likely to develop persistent antibodies. The antibody isotypes (IgM or IgG1-4), could not be used to discriminate between transiently and persistently positive patients.

Authors:
Lundkvist M, Engdahl E, Holmén C


Source:
Mult Scler. 2012 Oct 8. [Epub ahead of print]

Read the abstract

 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial